Summary.-We have studied the radiomodifying action in mouse skin of WR-2721 and misonidazole (MISO) when used alone or in combination. The radioprotection with WR-2721 was drug-dose dependent and highly influenced by the 02 concentration at the time of irradiation. Significant sensitization was observed with MISO, especially in air-breathing mice. The combination of WR-2721 and MISO produced a radiation response intermediate between the resistant and sensitive responses to either drug alone. The precise degree of sensitivity was dependent on the relative doses of protector and sensitizer. We have also studied the interaction of both drugs in terms of drug-induced lethality, which showed a clear toxic interaction. The WR-2721 LD50 was reduced by a factor of 1-4 with only 200 mg/kg of MISO. We conclude that the combination of WR-2721 and MISO shows an interaction in terms of drug toxicity and radiation response, such that the radioprotection of skin is reduced or even abolished with low doses of MISO.
and in radioprotectors for reducing normal-tissue injury (Phillips et al., 1973; Tanaka & Sugahara, 1980; Kligerman et al., 1980; Yuhas, 1981) . Radiosensitizers are believed to be tumour specific because they are only effective on hypoxic cells (Adams, 1978) and the radioprotectors to be normal-tissue specific because they selectively protect oxic cells (Harris & Phillips, 1971 ) and may be preferentially concentrated in normal tissues (Yuhas & Storer, 1969; Yuhas, 1980) . The possibility of combining the independent actions of these 2 groups of drugs in radiation therapy is attractive, especially since only low doses of both protectors and sensitizers can be used because of their systemic toxicity. Yuhas et al. (1977) and Sodicoff et al. (1979) indicated that the combination of WR-2721 with MISO in experimental radiotherapy was advantageous, since in their animal studies there was no additive drug toxicity, and neither compound interfered with the radiation-modifying effect of the other. MISO did not decrease the radioprotection of normal tissues and WR-2721 did not diminish tumour radiosensitization, thus increasing the therapeutic gain.
These results seem somewhat surprising in view of the many radiation chemistry and in vitro experiments using combinations of sensitizers and protectors. The published experimental results can be interpreted as a competition between these compounds for radical lesions, resulting in either fixation or repair of radiationinduced damage to biological targets (e.g ments, similar to those of Yuhas and his colleagues, in which the radioprotective effect of WR-2721 and the radiosensitizing action of MISO used alone and in combination, have been studied in both tumours and normal tissues. This paper reports the influence of MISO or additional 02 on the radioprotection observed in mouse skin with WR-2721. The tumour results will be presented elsewhere .
MATERIALS AND METHODS
Specific-pathogen-free female almino mice of the strain WHT (designated WHT/Gyf BSVS) aged 2-3 months, were used for all the experiments. The animals were caged in groups of 5 and given free access to food and water.
X-rays at 240 kV were generated in a Pantak X-ray set, filtered with 0-25 mm Cu and I 0 mm Al, to give a HVL of 1P3 mm Cu, and a dose rate of 2-2 Gy/min. For irradiation, unanaesthetized mice were loaded into individual lead boxes with their left hind limb gently immobilized in the beam (for details see Douglas & Fowler, 1976) .
Irradiations were performed at room temperature (23 + 2°C) with mice surrounded by air or 02-For the latter, the irradiation jig was placed inside a polythene bag, through which 100% 02 flowed at a rate of 6 1/min. Each dose group contained 5 mice.
WR-2721 (S-2-(3-aminopropylamino)ethyl phosphorothioic acid, kindly provided by the Developmental Program, Div. of Cancer Treatment, NCI, Bethesda, U.S.A.) was dissolved in saline for the first 2 experiments, and subsequently in distilled water. The WR-2721 doses used, whether alone or in combination with MISO, represented 20-50% of the LD50. The drug was given i.p. 30-40 min before irradiation. This has been shown to be an adequate interval for obtaining significant radioprotection in mouse skin Travis et al., 1982) . MISO (1-(2-nitroimidazole-1-yl)-3 methoxypropan-2-ol) kindly supplied by Roche Products Ltd., Welwyn Garden City) was dissolved in saline and given i.p. 15 min before WR-2721.
Skin reactions were scored 3 times a week from 8 until 35 days after irradiation, using an arbitary scale for erythema, desquamation 46 and ulceration, as previously described (Denekamp, 1973 for skin-reaction levels of 1--2. Correspondingly, for Fig. 6 the sensitizer enhancement ratio (SER) has been obtained from the dose of X-rays alone to X-rays plus MISO (or a combination), again for skin reactions of 1-2. Fig. 5 shows that the PF was lower in 02 than in air, but in both situations there was a decrease in skin radioprotection with increasing dose of MISO. Similarly (Fig. 6) pletely abolish it for certain drug combinations. In air the interaction effects were more marked, with steeper slopes for the curves of protection or sensitization as a function of increasing MISO or WR-2721 dose. These data indicate competition between the radiation-modifying actions of the sensitizer and the protector (see Table II ). . PF values for mice treated in air were obtained from 
DISCUSSION
The experiments reported here show that the radiosensitivity of mouse skin can be easily modified, either in the direction of greater sensitivity (by additional 02 or MISO) or in the direction of greater resistance (by WR-2721). These experiments were all performed on unanaesthetized mice. The data indicate that mouse skin is not sufficiently oxygenated to be fully radiosensitive when irradiated in air at 23 + 2°C. This result is in accord with the observations of several other authors (Fowler et al., 1965; Withers, 1967; . Although it is known that the radiosensitivity of mouse ----_ -J skin is readily influenced by environmental factors, including the surrounding rather than the inspired gas (Potten & Howard, 1969 ) a similar suboptimal oxygenation in air has been demonstrated for several other normal tissues in rodents (e.g. marrow, cartilage, intestine, oesophagus and testis, see review by Hendry, 1979) clearly the clinical relevance of these data depends upon whether the mouse resembles man in its tissue 02 levels, and particularly on whether there is a uniform low 02 tension which will influence the response to low X-ray doses, or a small proportion of severely hypoxic cells which will only become apparent at high X-ray doses (Hendry, 1979; .
Competitive interaction
The data presented in Figs. 2-6 and in Table I indicate that significant radioprotection of mouse skin was obtained over the WR-2721 dose range used, in both air and 02. The protection factors varied with drug dose, but were also strongly influenced by the 02 content of the inspired gas. These data indicate a competitive interaction between both sensitizers (02 and MISO) and WR-2721. This has previously been demonstrated in vitro with various sulphydryl compounds and electron-affinic radiosensitizers, for mammalian cells, for bacteria and for chemicals in solution (Dewey, 1963; Redpath & Willson, 1973; Chapman et al., 1973; Asquith et al., 1974; Hall et al., 1977; Cullen et al., 1980 , Michael & Harrop, 1980 Koch & Howell, 1980 , 1981 . The predominance of sensitization or protection has been shown to depend on the relative concentrations of the compounds and on the 02 status. Protection by sulphydryls is generally much greater in 02 than in hypoxic conditions (see Alper, 1979, for review) . Recently, however, the dependence of radioprotection on the 02 concentration has been shown to be more complex (Lunec et al., 1981; Denekamp et al., 1981) . The maximum radioprotection effect of dithioerythritol in vitro was obtained at 0.3%0 2, with less protection in anoxia or in air (Cullen et al., 1980) . Similarly, using the epidermal colony assay in vivo, the maximum effect of WR 2721 was seen in air, being reduced in 100% 02 or in low 02 concentrations (Denekamp et al., 1981) . Thus, both in vitro and in vivo the maximum radioprotection was obtained in the region of the "K" value* for 2, i.e. in the region where small changes in the available 02 have the most marked effect on the radiosensitivity of the system (Denekamp et al., 1981 . The early data of Dewey (1963) using very high concentrations of cysteine and highpressure 02 on Serratia marcescens accord with this conclusion.
Our data for MISO and WR 2721 also show a similar interaction. The radiation-modifying action of either compound could be reduced or eliminated by an appropriate dose of the other ( Table II ). These data are also consistent with the hypothesis of redox competition for radical fixation of the initial chemical lesions that lead to biological damage. They confirm in vivo the basic mechanisms which have been elucidated for competition between sensitizers and protectors in the variety of in vitro studies mentioned above.
Clinical application
Our data are more pessimistic in terms of the potential clinical usefulness of the drug combinations than earlier animal studies (Yuhas et al., 1977; Sodicoff et al., 1979; Grigsby & Maruyama, 1981) . We have been unable to confirm their statements that there was independent action of the 2 drugs, whether in terms of toxicity, tumour sensitization or skin protection.
The drug doses used in all these experi-* The "K" value is the [02] at which half the maximum sensitization is obtained (Alper & HowardFlanders, 1956 ).
ments are much higher than those likely to be tolerated in man. At present, the maximum tolerated dose clinically for MISO is 12 gm/M2 in 6-30 fractions (Dische et al., 1979) and for WR-2721 about 740 mg/M2 for a single dose (Blumberg et al., 1982) . However, the interaction that we have found between these compounds occurs at all dose levels tested, and presumably similar but correspondingly smaller effects will pertain at clinically relevant dose levels. Fig. 1 shows a very clear increase in WR-2721 toxicity if the animals are treated 15 min earlier with 200 or 670 mg/kg MISO. This is in marked contrast to the data of Yuhas et al. (1977) over the same MISO dose-range, but agrees well with the data of Grigsby & Maruyama (1981) .
Figs. 5 & 6 summarize our experiments on the interaction of MISO and WR-2721 on the skin response to radiation. All 4 panels show a dose-dependent decrease in protection or sensitization when the opposing agent is added. These data are similar to the effect observed by Yuhas et al. (1977) for marrow, and are more marked than the slight interaction they reported for skin reactions on tumour-bearing limbs (Yuhas et al., 1977) . We have deliberately chosen to study normaltissue responses in areas not compromised by a growing tumour, since the tumour growth may influence the skin reaction differentlv at different X-rays dose levels. We have allowed a longer time for WR-2721 penetration into the skin (30 min vs. 15 min) because earlier studies indicated that at least 30 min were needed to obtain maximum radioprotection Travis et al., 1982) . It seems unlikely that this detail of timing could account for the greater magnitude of interaction in our studies, since the protection factors with 400 mg/kg WR-2721 alone are similar in our work and in Yuhas's (1.36-1 55 vs. 145 -1 66). Furthermore the concept of competitive interaction is supported by the 02 data since a 5-fold increase in inspired 02 tension for 1-2 min before irradiation can also reduce the protection. Another report on the combined action of MISO and WR-2721 in normal tissues comes from Sodicoff et al. (1979) . They demonstrated no reduction in the protection factor for rat salivary glands in the presence of 200 mg/kg MISO, but these experiments used historical controls for the rats treated with no drug or WR-2721 alone. Grigsby & Maruyama (1981) showed interaction of WR-2721 and MISO on the oral mucosa. They found a significant reduction in WR-2721 radioprotection with all the MISO combinations tested. Thus the interaction of MISO and WR-2721 has been demonstrated in 3 tissues in vivo (skin, marrow and oral mucosa). Yuhas et al. (1977) also reported the effects of these 2 drugs separately and in combination on a tumour. They saw no interaction on the Line 1 carcinoma. By contrast we have observed a marked reduction in the MISO sensitization of 2 tumours (the fibrosarcoma SA FA and the anaplastic tumour CA MT) when the protector was added 30 min before irradiation (i.e. 15 min after the sensitizer). This interference with tumour sensitization was seen, even when no significant radioprotection by WR-2721 alone was obtained (Rojas et al. in preparation) . These data indicate to us that competitive interaction can also occur in tumours, and that the radioprotector can diffuse and penetrate into the hypoxic cells . In both skin and tumours the balance of the competition between protection and sensitization depends upon the relative doses of the 2 drugs.
These experiments show that the combination of MISO and WR-2721 provides a powerful tool for indirect investigation of the 02 tension in the critical cells of normal tissues. Previously, the lack of correlation between radioprotection and WR-2721 concentration in a tissue has been inexplicable. Denekamp et al. (1982) have proposed that small variations in intracellular 02 tensions in different tissues may explain some of the wide variation in the protection factors that have been reported. For example, in the lung, which shows high drug concentrations, the high local 02 tensions may compete effectively with the exogenous sulphydryls, reducing the overall protection. Other tissues could show little protection if their 02 tension were below the critical range. The greatest protection would then be expected in tissues with intracellular 02 tensions critically close to the oxygen "K" value. This hypothesis is obviously open to experimental verification by manipulation of the 02 content in the inspired gas.
In summary, we are not optimistic about the clinical potential of sensitizers and protectors used in combination. The additive toxicity, the reduced skin radioprotection and the reduced tumour sensitization indicate that a therapeutic advantage is unlikely.
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